Inebilizumab Production Cost Reports

The report provides a detailed analysis essential for establishing an inebilizumab production plant. It encompasses all critical aspects necessary for inebilizumab production, including the cost of inebilizumab production, inebilizumab plant cost, inebilizumab production costs, and the overall inebilizumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an inebilizumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Inebilizumab is a humanised monoclonal antibody targeting CD19 on B cells, utilised in pharmaceutical applications to treat autoimmune disorders. It was approved by the FDA in 2020 as Uplizna for neuromyelitis optica spectrum disorder (NMOSD) in AQP4-IgG-positive adults. It works by depleting pathogenic B cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), significantly reducing relapse rates as shown in the N-MOmentum trial. It has also gained approval for immunoglobulin G4-related disease (IgG4-RD), with ongoing trials exploring potential in myasthenia gravis, multiple sclerosis, and other B-cell-mediated conditions.

Inebilizumab’s market growth is driven by expanding regulatory approvals in rare autoimmune diseases, creating first-mover advantages in underserved areas. It's 2020 FDA approval for neuromyelitis optica spectrum disorder (NMOSD), followed by an anticipated 2025 FDA nod for IgG4-related disease (IgG4-RD) based on the MITIGATE trial showing 87% flare reduction, which boosts its market growth. Its recent 2026 European Commission approval as an add-on for generalised myasthenia gravis (gMG) boosts EU revenue potential amid limited competition.

Its pipeline expansions into conditions like multiple sclerosis, rising diagnosis rates due to increased awareness, and favourable reimbursement in high-value markets like the US, fuel the market expansion. However, high acquisition costs and emerging rivals like obexelimab impact industrial inebilizumab procurement. Furthermore, regulatory requirements, including prior authorisations, detailed diagnostic confirmation, TB screening, and hepatitis B testing before initiation, add administrative hurdles and delay access, influencing the overall procurement.

Raw Material for Inebilizumab Production

According to the inebilizumab production plant project report, the various raw materials for inebilizumab production include Chinese hamster ovary (CHO) cell suspension cultures.

Production Process of Inebilizumab

The extensive inebilizumab production cost report consists of the following major industrial production process:

1. Production via recombinant DNA technology: The production process of inebilizumab occurs via recombinant DNA technology in Chinese hamster ovary (CHO) cell suspension cultures. The synthesis begins with upstream production, where transfected CHO cells are expanded and fermented in bioreactors under optimised conditions to maximise yield and glycoengineered afucosylation for enhanced ADCC potency. The harvested cell culture fluid undergoes downstream purification through multi-step chromatography, including protein A affinity, ion-exchange, and hydrophobic interaction. The purification is coupled with viral inactivation, filtration, and ultrafiltration/diafiltration to remove impurities like host cell proteins, DNA, and aggregates, ensuring high purity and batch consistency.

Properties of Inebilizumab

Inebilizumab (Uplizna) is a humanised, afucosylated IgG1κ monoclonal antibody with a molecular weight of about 149 kDa. It consists of two heavy chains (~49 kDa each) and two light chains (~24 kDa each), linked by 16 disulfide bonds and N-glycosylated at Asn-301, with an extinction coefficient of 1.35 mL/mg/cm and a pI of 7.9-8.5. It is supplied as a sterile, clear to slightly opalescent, colourless to pale yellow liquid at 100 mg/10 mL (10 mg/mL), buffered with histidine, sodium chloride, trehalose dihydrate, and polysorbate 80. It possesses biphasic pharmacokinetics (central Vd 2.95 L, peripheral 2.57 L, clearance 0.19 L/day, half-life ~18 days), and chemical stability under refrigeration. Its afucosylated Fc enhances ADCC potency against CD19 via strong FcγRIIIa binding and proteolytic degradation akin to endogenous IgG.